Merck & Co., Inc.'s Q3 earnings report is anticipated on 31st October — next Thursday. Despite strong Q2 performance, Merck's stock fell due to a guidance downgrade related to issues with key ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a 14-1 vote, the panel moved to expand its usage recommendation for both Pfizer’s Prevnar 20 and Merck’s Capvaxive to include all adults aged 50 and older as well as adults between 19 and ...

Merck & Co. is putting down $30 million upfront to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma (GBM).

Gilead Sciences and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to sustained suppression of the virus out to 48 weeks in a ...

Oct 23 (Reuters) - Merck (MRK.N), opens new tab has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

(Reuters) - Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday. As part of ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

“We are honored to have Merck recognize the potential of our science, and as an oncology company, they are perfectly positioned to advance our innovations through clinical trials and ...